rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MDWD
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      MediWound Ltd. Q3 2026 Earnings Call Summary
      Nov 12Yahoo FinanceMDWD
      What MediWound (MDWD) Said on Its Q3 Earnings Call
      Nov 12Yahoo FinanceMDWD
      MediWound Q3 2026 Earnings Call Transcript
      Nov 12BenzingaMDWD
      MediWound’s Burn Drug Is Gaining Speed. Its Next Target Could Be Much Bigger (NASDAQ: MDWD)
      Nov 12BenzingaMDWD
      Mediwound earnings beat by $0.06, revenue fell short of estimates
      Nov 12Investing.comMDWD
      MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates
      Nov 12Yahoo FinanceMDWD
      MediWound: Q3 Earnings Snapshot
      Nov 12Yahoo FinanceMDWD
      MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update

      EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Third Quarter Revenue of $3.6 Million; 2026 Revenue Outlook Dependent on Ongoing U.S. Government Discussions Balance Sheet Strengthened by $17.25 Million in Gross Proceeds from Underwritten Public Offering Following Quarter-End Conference Call Today at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 12, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in

      Nov 12Yahoo FinanceMDWD
      After Smith+Nephew's $34 Billion Merger Collapse, This Wound Care Stock Is Worth a Look (NASDAQ: MDWD)
      Nov 9BenzingaMDWDSNN
      MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares
      Nov 5Yahoo FinanceMDWD
      MediWound (MDWD) Moves 6.1% Higher: Will This Strength Last?

      MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

      Nov 5Yahoo FinanceMDWD
      MediWound announces $15 million share offering
      Nov 3Investing.comMDWD
      MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares
      Nov 3Yahoo FinanceMDWD
      MediWound’s EscharEx Strategy May Be Ahead of the Game as FDA Puts Chronic Wounds in Focus (Nasdaq: MDWD)
      Nov 3BenzingaMDWD
      MediWound to Report Third Quarter 2026 Financial Results
      Oct 29Yahoo FinanceMDWD
      Chronic Wounds Pipeline 2026: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE
      Sep 29BarchartMDWD
      TD Cowen reiterates MediWound stock rating ahead of trial data
      Sep 24Investing.comMDWD
      Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), Mediwound (MDWD)

      Detailed price information for Ligand Pharm (LGND-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailLGNDMDWD
      Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD) - MediWound (NASDAQ:MDWD), Vericel (NASDAQ:V

      WSW, NY, September 22nd, 2026, FinanceWireOn September 22, MediWound disclosed that the Department of War had added to a program it has been backing since long before most investors had heard of the company. What it

      Sep 22BenzingaMDWDVCEL
      MediWound receives $3.3M from DoD for NexoBrid development
      Sep 22Investing.comMDWD
      MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
      Sep 22Yahoo FinanceMDWD
      MediWound at H.C. Wainwright: value trial looms as catalyst
      Sep 14Investing.comMDWD
      Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification

      Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification DSMB did not identify safety concerns in pre-specified review; interim assessment and enrollment completion remain on track for end of the first quarter of 2027 YAVNE, Israel, September 14, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the independent Data and Safety Monitoring Board (DSMB)

      Sep 14Yahoo FinanceMDWD
      MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference

      MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference YAVNE, Israel, September 2, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will take place September 14–16, 2026, at the Lotte New York Palace Hotel in New York City. The f

      Sep 2Yahoo FinanceMDWD
      New Research Estimates a $4 Billion Market by 2028, and MediWound Thinks It May Have a Solution (Nasdaq: MDWD)
      Aug 25BenzingaMDWD

      This is the newest page. Registered accounts read further back.